ENSC Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. (ENSC) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is $0.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +17.9% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Ensysce Biosciences, Inc.
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology